血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Vasoactive Intestinal Peptide (VIP) ,etc. by FLIA (Flow Luminescence Immunoassay)
PHM27; Intestinal peptide PHV-42; Peptide histidine valine 42; Peptide histidine methioninamide 27
（注：?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) ）
- 編號(hào)ULMA380Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.49-500pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.163 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1179 ¥ 1225 ¥ 1293 ¥ 1383 ¥ 1474 ¥ 1610 ¥ 1814 ¥ 2268 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-101 | 82 |
| EDTA plasma(n=5) | 90-101 | 94 |
| heparin plasma(n=5) | 98-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-101% | 82-104% | 82-103% | 91-105% |
| EDTA plasma(n=5) | 83-101% | 78-102% | 91-98% | 92-101% |
| heparin plasma(n=5) | 89-103% | 80-103% | 81-105% | 88-102% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA380Hu01 | 血管活性腸肽(VIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| USPA380Hu01 | 血管活性腸肽(VIP)合成多肽 | Immunogen; Blocking Peptide. |
| UPAA380Hu01 | 血管活性腸肽(VIP)多克隆抗體 | WB; IHC; ICC; IP. |
| UMAA380Hu22 | 血管活性腸肽(VIP)單克隆抗體 | WB |
| UMAA380Hu21 | 血管活性腸肽(VIP)單克隆抗體 | WB |
| UCEA380Hu | 血管活性腸肽(VIP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA380Hu | 血管活性腸肽(VIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA380Hu11 | 血管活性腸肽(VIP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinical Genetics | VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population [Wiley: source] |
| Human immunology | Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy [Pubmed: 23800435] |
| Headache: The Journal of Head and Face Pain | CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine [Onlinelibrary: head.12372] |
| World J Gastroenterol | Roles of sphincter of Oddi motility and serum vasoactive intestinal peptide, gastrin and cholecystokinin octapeptide [NCBI: PMC4000510] |
| Cephalalgia? | Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine [Pubmed:24847167] |
| J Huazhong Univ Sci Technolog Med Sci. | Clinical study of electro-acupuncture treatment with different intensities for functional constipation patients [Pubmed:25318892] |
| PLOS ONE | Aqueous Fraction of Beta vulgaris Ameliorates Hyperglycemia in Diabetic Mice due to Enhanced Glucose Stimulated Insulin Secretion, Mediated by Acetylcholine and GLP-1, and Elevated Glucose Uptake via Increased Membrane Bound GLUT4 Transporters [Pubmed:25647228] |
| PLOS ONE | Aqueous Fraction of [PubMed: 25647228] |
| Pharmacol Res | Oral curcumin has anti-arthritic efficacy through somatostatin generation [PubMed: 25836921] |
| World J Gastroenterol | Effects of sphincter of Oddi motility on the formation of cholesterol gallstones [Pubmed:27350732] |
| Annals of Allergy, Asthma and Immunology | Effect of acupuncture on house dust mite specific IgE, substance P, and symptoms in persistent allergic rhinitis [Pubmed:27156748] |
| Cephalalgia. | Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients [Pubmed:27250233] |
| Headache | No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine [pubmed:27634731] |
| Sci Rep. | Using the "target constituent removal combined with bioactivity assay" strategy to investigate the optimum arecoline content in charred areca nut. [pubmed:28054652] |
| BMC Complementary and Alternative Medicine | [6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Leprdb/db type 2 diabetic mice [10.1186/s12906-017-1903-0] |
| Applied Biological Chemistry | Positive enhancement of Lactobacillus fermentum HY01 on intestinal movements of mice having constipation [10.1007/s13765-017-0327-3] |
| Journal of Periodontology | Salivary neuropeptides, stress, and periodontitis [Pubmed:28914594] |
| Evidence-Based?Complementary and Alternative Medicine | Home-Based Transcutaneous Neuromodulation Improved Constipation via Modulating Gastrointestinal Hormones and Bile Acids [Pubmed:29853946] |
| Revista do Instituto de Medicina Tropical de S?o Paulo | Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients [Pubmed: 30365640] |
| Journal of Veterinary Science | Serum Levels of Neuropeptides in Cows with Left Abomasal Displacement [Pubmed: 30562932] |
| Science?of?Food?and?Agriculture | Protective Effect of Silkworm Pupa Oil on Hydrochloric Acid/Ethanol‐Induced Gastric Ulcer [Pubmed: 30479041] |
| MOLECULAR BIOLOGY REPORTS | Serum CGRP, VIP, and PACAP usefulness in migraine: a case–control study in chronic migraine patients in real clinical practice [Pubmed: 32951099] |
| Journal of Cystic Fibrosis | Disrupted local innervation results in less VIP expression in CF mice tissues [Pubmed: 32600901] |
| Biomedical Journal of Scientific & Technical Research | Anti-Inflammatory and Pro-Inflammatory Neuropeptides in Dilative Cardiomyopathy are there Relations to Psychophysical Stress? [] |
| Journal of tranditional chinese medical sciences | Ganjiang granule regulates cecal microflora and serum biochemical components in a rat model of constipation-predominant irritable bowel syndrome [] |
| J Cyst Fibros | VIP reduction in the pancreas of F508del homozygous CF mice and early signs of Cystic Fibrosis Related Diabetes (CFRD) [34034984] |
| Neurol Sci | Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case–control study [34698942] |
| Endocr J | A clinical analysis on functioning pancreatic neuroendocrine tumors (focusing on VIPomas): a single-center experience [Pubmed:35644576] |
